eFFECTOR Therapeutics announced that the Company has terminated its employees and will wind down it operations, including seeking potential strategic alternatives for the Company’s development programs. This decision was made at a special meeting of the board of directors. Further, as previously disclosed, the Company’s securities do not presently meet the continued listing requirements of the Nasdaq Stock Market and its securities would be subject to delisting if the Company fails to regain compliance during the required compliance period. The Company plans to voluntarily request a delisting of its securities and expects its securities to be delisted in the near term. The board of directors appointed Craig R. Jalbert, age 62, as the Company’s CEO, President, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EFTR:
- eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
- eFfector Therapeutics to collaborate with Dana-Farber Cancer Institute
- eFfector Therapeutics reports Q1 EPS ($2.16), consensus ($2.16)
- eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update